UCLA Technology Development Group

Bio-Zipper Tissue Closure Device

2021 UCLA Innovation Fund Pitch Day

Presented by: Renea Sturm, MD FAAP Assistant Professor Dept of Urology, UCLA


The Bio-Zipper: A Surgical Closure Device

<u>Need</u>: 680K annual urologic reconstructions in U.S.

Solution: Reinforces suture lines in complex surgical reconstruction

<u>Predicted Impact</u>: Decreases 30-day complications & readmissions ~20% with savings of \$5,600 / procedure¹

Development Stage: Working prototype in preclinical testing and ongoing material optimization



The Bio-Zipper Multidisciplinary Team

Bio-Zipper Founding Team



Renea Sturm, MD Asst Prof, Urology Surgeon-Scientist UCLA



George E. Aninwene II, PhD Project Scientist, Urology BioE, Entrepreneurship UCLA



Ali Khademhosseini, PhD

CEO, Professor Materials Scientist TIBI

Research Team

Hanjun Kim, PhD, DVM Hossein Montazerian, BioE, UCLA Peyton Tebon, BioE, UCLA Kalpana Mandal, PhD, Physics, TIBI Reihaneh Haghniaz, PhD, Biotechnology, TIBI Marvin Mecwan, PhD BioE, TIBI M. Ali Darabi, PhD, Materials TIBI

Advisory Team

UCLA


Karim Chamie, MD Urologic Oncologist, UCLA Gladys Ng, MD, Urologic Reconstruction, UCLA Jennifer McCaney, PhD, UCLA Biodesign Nirav Kamdar MD, UCLA Biodesign

Biodesign

Program



Lower Urinary Tract Reconstruction



Limits of Suturing in High-Risk Urologic Surgery

Neobladder Stats:


~1-2 feet of bowel

6 hour operative time

\$35K operative cost¹

Complications & Readmissions: 30-68%²

Cost: ~\$30K per Complication²



1.Farber, Bladder Cancer. 2018 2.Barbieri, Curr Bladder Dysf Rep. 2016 3.Hautmann, BJU Int. 2010


(3)



The Bio-Zipper provides Needed Tissue Support

A novel surgical device that:

- Leverages cutting-edge biomaterials
- Provides fast, consistent luminal closure
- Readily applied within standard procedure
 using open or robotic platforms




Customer Discovery

> 150 interviews


Conclusions

Decreased Complications + Readmissions: The top priority



CORPS


Surgical Closure Devices: A Growing Market



Based on procedural volumes (UCLA) extrapolated to the U.S. Estimated \$500/device cost, 2 devices per LUTR, 1 for most other applications




Range of Elastomer Strengths (PGS) produced correspond with Target Tissue




Ileum (Small Intestine) tissue (n=6); PGS: Bio-Zipper team data, *6Tissue Data Adapted from Davis, Urol. 2021

Modification of PGS Yields Adhesive Polymer



11

Functionalized PGS increases the Pressure and Volume required for Bladder to Leak



Physiologic Bladder Pressure: $2.0 \rightarrow 7.8 \text{ kPa}^7$

Porcine Bladder Burst Pressure Analysis: Incision was made on porcine bladder and closed with ether two running sutures or two running sutures and adhesive patch. (n=3, p <0.05)

12


Intellectual Property protects Device Design

Patent Filed – <u>Bio-Zipper Surgical Device</u>


- Provisional PCT/US20/55766
- PCT application pending (published Apr-2021)

Novel Features

- Flexible bioabsorbable backbone
- Bio-adhesive Mechanism
- Methods to pull together device across closure line







Surgical Closure Landscape

Device	Reinforces Suture Lines	Bio-absorbable	Designed for Urology	Reduces Complications in UTR
Bio-Zipper	\checkmark	\checkmark	\checkmark	\checkmark
Sutures	_	\checkmark	\checkmark	
Medical Adhesives	\checkmark	\checkmark		
Staplers	\checkmark			




Path to Market

Early Partnerships With Larger Surgical Device Companies

- Optimize device production
- Expedite Initial Clinical Trials
- Leverage Their Market Penetration

Initial Sales To Academic Hospitals

• Through Industry Partners





Active M&A and VCs in Surgical Biopolymers

Product		Technical Specs	Clinical Application	Exit
Tissium		Biomorphic, applied viscous polymer, blue light activated	 Cardiovascular, CE Mark product adjuncts to sutures GI, ear, nose, throat, nerve reconstruction Suture line reinforcement 	<u>8/31/2021</u> Series C VC: \$70.2M Valuation: \$259.65M
Adhesys Medical	VIVO Alova tha de tra wer englissment	Polyurethane prepolymer, amino- based curing agent	 Vascular reconstructions Suture line reinforcement in cardiovascular 	<u>4/7/2017</u> Acquired by Grunenthal, terms undisclosed
Bio-Zipper	Simile	PGS - prefabricated polymer and bio- adhesive	 Urologic procedures Future gynecologic and GI applications Suture line reinforcement 	<u>With the</u> Innovation Fund's help!

Potential Challenges

Challenge	De-risking Method
Technical	
Adhesive stability on backbone Non-toxic degradation Ease of application	 Surface modification of bulk material Conduct in vivo experiments Simulation trials with surgeons

Potential Challenges

Challenge	De-risking Method
Technical	
Adhesive stability on backbone	Surface modification of bulk material
Non-toxic degradation	Conduct in vivo experiments
Ease of application	Simulation trials with surgeons
Market	
Multiple players in surgical closures	Urologic focused need, patent submission


Potential Challenges

Challenge	De-risking Method	
Technical		
Adhesive stability on backbone	Surface modification of bulk material	
Non-toxic degradation	Conduct in vivo experiments	
Ease of application	Simulation trials with surgeons	
Market		
Multiple players in surgical closures	Urologic focused need, patent submission	
Regulatory		
Planned <i>de novo</i> device submission	Show predicate devices & safe use of component materials in FDA approved devices; 510K if required	



Development Timeline

UCL




Bio-Zipper: An Impactful, Novel Solution

<u>Novelty</u>: Materials, Bio-Adhesive, Urologic Application (Open & Robotic)

Predicted Impact: Decreases 30-day complications & readmissions ~20% with savings of \$5,600 / procedure¹

Future Applications:

CV, Pulm, GI, Drug Delivery, Smart Sensing





UCLA Technology Development Group

Bio-Zipper Tissue Closure Device

2021 UCLA Innovation Fund Pitch Day

THANK YOU FOR YOUR SUPPORT